<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="7682">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03006926</url>
  </required_header>
  <id_info>
    <org_study_id>E7080-J081-116</org_study_id>
    <nct_id>NCT03006926</nct_id>
  </id_info>
  <brief_title>A Trial of Lenvatinib Plus Pembrolizumab in Subjects With Hepatocellular Carcinoma</brief_title>
  <official_title>An Open-Label Phase 1b Trial of Lenvatinib Plus Pembrolizumab in Subjects With Hepatocellular Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eisai Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eisai Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label Phase 1b study designed to evaluate the tolerability and safety of
      lenvatinib in combination with pembrolizumab in participants with hepatocellular carcinoma
      (HCC).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 28, 2017</start_date>
  <completion_date type="Anticipated">June 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>No masking</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with any serious adverse event and number of participants with any non-serious adverse event</measure>
    <time_frame>For each participant, from the first participant first dose until 30 days after the last dose (up to approximately 2 years)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Dose-limiting toxicity (DLT) of lenvatinib and pembrolizumab during Cycle 1</measure>
    <time_frame>Up to 21 Days (Cycle 1)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective response rate (ORR) based on modified Response Evaluation Criteria In Solid Tumors (mRECIST)</measure>
    <time_frame>From date of first dose of study drug until disease progression, development of unacceptable toxicity, withdrawal of consent, or up to approximately 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response (DOR) based on mRECIST</measure>
    <time_frame>From the first documentation of complete response (CR) or partial response (PR) to the date of first documentation of disease progression or death (whichever occurs first), or up to approximately 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean maximum concentration (Cmax) of lenvatinib</measure>
    <time_frame>Cycle 1, Day 1: predose of pembrolizumab; 1, 2, 4, 8, and 24 hours postdose of lenvatinib. Cycle 1, Day 15: predose of lenvatinib; 1, 2, 4, 8, and 24 hours postdose of lenvatinib</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean time to reach maximum concentration (Tmax) of lenvatinib</measure>
    <time_frame>Cycle 1, Day 1: predose of pembrolizumab; 1, 2, 4, 8, and 24 hours postdose of lenvatinib. Cycle 1, Day 15: predose of lenvatinib; 1, 2, 4, 8, and 24 hours postdose of lenvatinib</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean terminal half-life (t1/2) of lenvatinib</measure>
    <time_frame>Cycle 1, Day 1: predose of pembrolizumab; 1, 2, 4, 8, and 24 hours postdose of lenvatinib. Cycle 1, Day 15: predose of lenvatinib; 1, 2, 4, 8, and 24 hours postdose of lenvatinib</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean area under the drug concentration-time curve (AUC) of lenvatinib</measure>
    <time_frame>Cycle 1, Day 1: predose of pembrolizumab; 1, 2, 4, 8, and 24 hours postdose of lenvatinib. Cycle 1, Day 15: predose of lenvatinib; 1, 2, 4, 8, and 24 hours postdose of lenvatinib</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean apparent total clearance (CL/F) of lenvatinib</measure>
    <time_frame>Cycle 1, Day 1: predose of pembrolizumab; 1, 2, 4, 8, and 24 hours postdose of lenvatinib. Cycle 1, Day 15: predose of lenvatinib; 1, 2, 4, 8, and 24 hours postdose of lenvatinib</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean apparent volume of distribution (Vz/F) of lenvatinib</measure>
    <time_frame>Cycle 1, Day 1: predose of pembrolizumab; 1, 2, 4, 8, and 24 hours postdose of lenvatinib. Cycle 1, Day 15: predose of lenvatinib; 1, 2, 4, 8, and 24 hours postdose of lenvatinib</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean measured concentration at the end of a dosing interval (Ctrough) of pembrolizumab</measure>
    <time_frame>Day 1 of Cycles 1, 2, 4, 6, and 8 and Day 1 in every 4 cycles after Cycle 8: predose of pembrolizumab. End of treatment: within 30 days after discontinuation or until the initiation of other anticancer treatment, whichever is earlier</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean clearance (CL) of pembrolizumab</measure>
    <time_frame>Day 1 of Cycles 1, 2, 4, 6, and 8 and Day 1 in every 4 cycles after Cycle 8: predose of pembrolizumab. End of treatment: within 30 days after discontinuation or until the initiation of other anticancer treatment, whichever is earlier</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with anti-drug antibodies (ADA) for pembrolizumab</measure>
    <time_frame>Day 1 of Cycles 1 and 6: predose of pembrolizumab</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Hepatocellular Carcinoma</condition>
  <arm_group>
    <arm_group_label>lenvatinib 8 or 12 mg plus pembrolizumab 200 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive oral lenvatinib at a starting dose of 8 or 12 milligrams (mg) once a day (QD) in combination with intravenous pembrolizumab 200 mg every 3 weeks (Q3W) on a 21-day treatment cycle. The starting dose of lenvatinib will be based on Baseline body weight. Participants weighing greater than or equal to 60 kilograms (kg) will receive 12 mg QD; participants weighing less than 60 kg will receive 8 mg QD.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>lenvatinib</intervention_name>
    <description>lenvatinib capsules</description>
    <arm_group_label>lenvatinib 8 or 12 mg plus pembrolizumab 200 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>pembrolizumab</intervention_name>
    <description>pembrolizumab intravenous infusion</description>
    <arm_group_label>lenvatinib 8 or 12 mg plus pembrolizumab 200 mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Confirmed diagnosis of hepatocellular carcinoma (HCC)

          -  HCC for which no other appropriate therapy is available. Note: Expansion Part: No
             prior systemic therapy for advanced/unresectable HCC

          -  Stage B (not applicable for transarterial chemoembolization [TACE]), or stage C based
             on Barcelona Clinic Liver Cancer (BCLC) staging system

          -  At least 1 measurable target lesion according to modified Response Evaluation
             Criteria in Solid Tumors (mRECIST)

          -  Child-Pugh score A

          -  Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) of 0 to 1

          -  Adequately controlled blood pressure

          -  Adequate renal function

          -  Adequate bone marrow function

          -  Adequate blood coagulation function

          -  Adequate liver function

          -  Males or females age â‰¥ 18 years at the time of informed consent

          -  Voluntary agreement to provide written informed consent and the willingness and
             ability to comply with all aspects of the protocol

        Exclusion Criteria:

          -  Prior treatment with lenvatinib or any anti-PD-1, anti-PD-L1, or anti-PD-L2 agent

          -  Any current brain or subdural metastases

          -  Active malignancy (except for HCC or definitively treated melanoma in-situ, basal or
             squamous cell carcinoma of the skin, or carcinoma in-situ of the cervix) within the
             past 36 months

          -  Any medical or other condition which, in the opinion of the investigator, would
             preclude participation in a clinical trial
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Customer Joy Department. EJ</last_name>
    <phone>81-120-161-454</phone>
  </overall_contact>
  <location>
    <facility>
      <address>
        <city>Kashiwa</city>
        <state>Chiba</state>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Chuo-ku</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <lastchanged_date>March 31, 2017</lastchanged_date>
  <firstreceived_date>December 27, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>hepatocellular carcinoma</keyword>
  <keyword>E7080</keyword>
  <keyword>lenvatinib</keyword>
  <keyword>pembrolizumab</keyword>
  <keyword>Japan</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Lenvatinib</mesh_term>
    <mesh_term>Pembrolizumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
